Herantis Pharma Oyj (HEL:HRTIS)
Finland · Delayed Price · Currency is EUR 1.650
+0.030 (1.85%)
Aug 28, 2026, 6:29 PM EET
Herantis Pharma Oyj Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.74 | 0.75 | 0.63 | 5.5 | 5.04 | 6.44 |
Short-Term Investments | 2.77 | 1.85 | 1.5 | 0.99 | 0.96 | 0.99 |
Cash & Short-Term Investments | 3.51 | 2.6 | 2.13 | 6.49 | 5.99 | 7.42 |
Cash Growth | -23.12% | 21.66% | -67.10% | 8.30% | -19.31% | -44.28% |
Other Receivables | 0.12 | 0.04 | 0.41 | 0.24 | 0.2 | 0.12 |
Receivables | 0.12 | 0.04 | 0.41 | 0.24 | 0.2 | 0.12 |
Prepaid Expenses | 0.41 | 0.03 | 0.03 | 0.02 | 0.04 | 0.06 |
Total Current Assets | 4.04 | 2.67 | 2.57 | 6.75 | 6.23 | 7.6 |
Long-Term Deferred Charges | - | - | - | - | - | 0.16 |
Total Assets | 4.04 | 2.67 | 2.57 | 6.75 | 6.23 | 7.76 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.58 | 0.39 | 0.28 | 0.75 | 0.66 | 0.79 |
Accrued Expenses | 0.76 | 0.44 | 0.32 | 1.17 | 1.06 | 0.73 |
Current Portion of Long-Term Debt | 0.01 | 0 | 0 | 0 | 0.15 | 0.91 |
Current Portion of Leases | - | 0.04 | - | - | - | 0.13 |
Other Current Liabilities | 0.05 | 0.03 | 0.03 | 0.06 | 0.03 | 0.05 |
Total Current Liabilities | 1.4 | 0.91 | 0.63 | 1.99 | 1.9 | 2.61 |
Long-Term Debt | 0.02 | 0.02 | 0.02 | 0.03 | 4.39 | 6.29 |
Other Long-Term Liabilities | 3.42 | 3.42 | 2.16 | - | - | 0 |
Total Liabilities | 4.83 | 4.36 | 2.81 | 2.02 | 6.29 | 8.9 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Retained Earnings | -90.03 | -86.71 | -80.07 | -75.1 | -75.38 | -67.75 |
Comprehensive Income & Other | 89.16 | 84.94 | 79.75 | 79.75 | 75.24 | 66.53 |
Shareholders' Equity | -0.8 | -1.69 | -0.24 | 4.73 | -0.06 | -1.14 |
Total Liabilities & Equity | 4.04 | 2.67 | 2.57 | 6.75 | 6.23 | 7.76 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.02 | 0.07 | 0.03 | 0.03 | 4.54 | 7.33 |
Net Cash (Debt) | 3.49 | 2.53 | 2.1 | 6.45 | 1.45 | 0.09 |
Net Cash Growth | -23.14% | 20.10% | -67.39% | 345.14% | 1482.98% | -98.50% |
Net Cash Per Share | 0.14 | 0.11 | 0.10 | 0.38 | 0.10 | 0.01 |
Filing Date Shares Outstanding | 26.5 | 24.09 | 20.16 | 20.16 | 16.91 | 11.1 |
Total Common Shares Outstanding | 26.5 | 24.09 | 20.16 | 20.16 | 16.91 | 11.1 |
Working Capital | 2.64 | 1.76 | 1.94 | 4.76 | 4.33 | 4.99 |
Book Value Per Share | -0.03 | -0.07 | -0.01 | 0.23 | -0.00 | -0.10 |
Tangible Book Value | -0.8 | -1.69 | -0.24 | 4.73 | -0.06 | -1.14 |
Tangible Book Value Per Share | -0.03 | -0.07 | -0.01 | 0.23 | -0.00 | -0.10 |